AZN Related Hot List
-
AstraZeneca plc (AZN) Tops Q3 EPS by 30c
-
AstraZeneca (AZN) Tops Q2 EPS by 24c; Guides Higher
-
Mylan (MYL) Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex
-
Dynavax Technologies (DVAX) Announces Extension of AstraZeneca (AZN), Eligible To Receive $136M
-
Targacept (TRGT) and Partner AstraZeneca (AZN) Said AZD3480 Did Not Meet Primary Endpoints
-
AstraZeneca (AZN) Sees FY08 Adj-EPS at Low End of $4.90-$5.05 Range
-
AstraZeneca (AZN) Tops Q3 Views; Raises Guidance
-
AstraZeneca (AZN) and Targacept (TRGT) Announce from Phase 2b Study of AZD3480 Did Not Meet Criteria
-
Bristol-Myers Squibb (BMY) Reports Q2 Earnings, Raises FY07 EPS and Guides for FY08
-
AstraZeneca PLC (AZN) Acquires MedImmune (MEDI) for $58/Share
-
AtheroGenics (AGIX) Reports ARISE Phase III Clinical Study Doesn't Meet Enpoint
-
Palatin Technologies (PTN) Higher On Collaboration Deal with AstraZeneca
-
Targacept (TRGT) Receives $20 Million Milestone Payment from AstraZeneca (AZN)
-
Renovis (RNVS) Said NXY-059 Fails to Meet Trial Endpoints
-
POZEN (POZN) Receives $40M Payment from AstraZeneca (AZN); Revised 2006 Guidance
-
Dynavax (DVAX) In Collaboration with AstraZeneca for TLR-9, Could Be Worth Up to $136M
-
POZEN (POZN) in Global Collaboration with AstraZeneca for Pain Treatment
-
AstraZeneca (AZN) Acquires Cambridge Antibody (CATG)
-
AstraZeneca (AZN) Tops Q1 EPS Views; Guided Higher
-
PDII Announces Termination of AstraZeneca Fee-for-Service Contract
-
AZN withdraws Exanta, due to new safety data - Bloomberg
-
PDII Lower on Expected Reductions from AstraZeneca
-
AGIX and AZN in License and Commercialization Agreement Worth Up to $1B
-
AVN in Deal with AstraZeneca PLC
-
New Study Shows Side Effects from AZN's Crestor is Higher Than Other Statins
-
RNVS Says Saint I Phase III Trial Demonstrated a Statistically Significant Reduction in Disability
-
GNTA Genasense Increases Anti-Tumor Activity of Iressa
-
AZN Gets FDA Approval for NEXIUM
Back to AZN Stock Lookup
